Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment

Next Previous
Search
Trial Profile

An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavodelpar (Primary)
  • Indications Mitochondrial myopathies
  • Focus Adverse reactions
  • Sponsors Reneo Pharmaceuticals

    • Most Recent Events

    • 23 Jun 2020 According to a Reneo Pharmaceuticals media release, this study is informing the design of a large, global PMM clinical trial (CT profile 323983).Reneos Chief Medical Officer Dr. Alejandro Dorenbaum will be discussing about this clinical study and plans for the next study at UMDF Power Surge 2020. The presentation will take place 26th Jun 2020.
    • 23 Jun 2020 Results (safety data and exploratory endpoint results) from this study presented in a Reneo Pharmaceuticals media release.
    • 22 Apr 2020 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top